Nasdaq GlobeNewswire

DSM Sinochem Pharmaceuticals Initiates Patent Litigation Against CSPC Pharmaceutical Group Ltd., Inner Mongolia Changsheng Pharmaceutical Company Ltd., and CSPC Zhangnuo Pharmaceutical (Shijiazhuan...

Del

DSM Sinochem Pharmaceuticals (DSP), the global leader in production and commercialization of  sustainable, enzymatic antibiotics, next generation statins and anti-fungals, announced that it has  filed a lawsuit against CSPC Pharmaceutical Group Ltd., Inner Mongolia Changsheng Pharmaceutical Company Ltd., and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) Company Ltd. for patent infringement.

SINGAPORE, Oct. 09, 2017 (GLOBE NEWSWIRE) -- DSM Sinochem Pharmaceuticals announced today that its wholly owned subsidiary, DSM Sinochem Pharmaceuticals Netherlands B.V. filed a lawsuit against CSPC Pharmaceutical Group Ltd., Inner Mongolia Changsheng Pharmaceutical Company Ltd., and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) Company Ltd. ("CSPC") for patent infringement in the District Court of The Hague, Afdeling Handel (commercial division), Netherlands, for patent infringement of the Dutch part of European Patent Number 1,610,766 B1. This patent, which is owned by DSP, describes and claims amoxicillin trihydrate having a low free water content and processes for the manufacture thereof. By its complaint, DSP seeks compensation for damages and a permanent injunction to prevent the infringing manufacture, use, importation and sale of CSPC's amoxicillin active pharmaceutical ingredient, and/or any drug product that utilizes the active pharmaceutical, in the Netherlands.

" DSP has a world class intellectual property (IP) portfolio relating to our innovative, sustainable, and environmental friendly amoxicillin technology,"  said Karl Rotthier, CEO at DSP.   "After having previously filed patent litigation against Sinopharm Weiqida Pharmaceutical for patent infringement in India and the Netherlands in January 2017, DSP will continue to rigorously enforce its IP assets worldwide against any additional potential infringers as it continues to invest in its innovative R&D programs directed to enzymatic, sustainable antimicrobials and statins."

DSM Sinochem Pharmaceuticals
DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.

Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company active in health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.

Forward-looking statements
This press release may contain forward-looking statements with respect to DSM Sinochem Pharmaceuticals' (DSP) future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSP and information currently available to the company. DSP cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSP has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

Please visit www.dsm-sinochem.com for more information or contact 
DSM Sinochem Pharmaceuticals Corporate Communications
Alice Beijersbergen, Global Director Branding & Communications 
E-Mail: communications@dsm-sinochem.com

DSM Sinochem Pharmaceuticals
Corporate Communications
www.dsm-sinochem.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DSM Sinochem Pharmaceuticals via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Medibio Corporate Health Extends Global Footprint Signing Contract with Jacobs Engineering25.5.2018 16:38Pressemelding

Jacobs, one of the world's largest engineering and environmental consultancy groups, has more than 70,000 employees globally SYDNEY, Australia and MINNEAPOLIS, May 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, today announced a significant contract for Medibio's Corporate Health product with Dallas, TX-based Jacobs Engineering across their Asia Pacific, Middle East, and European divisions. Through the Mental Health Check-In, companies can offer employees an end-to-end mental health program, direct to their devices, to see how the mind and body are tracking. It's a personalized, private, and objective way to see the unseeable: mental health issues in the workplace. Employees are provided the opportunity to confidentially check-in on their mental health and receive personalized confidential results from both an objective biometric screening in conjunction with a 12-minute subjective survey. Employers receive

VIRGIN PULSE ANNOUNCES INDUSTRY-LEADING GDPR COMPLIANCE25.5.2018 14:00Pressemelding

Virgin Pulse Extends the GDPR's Strong Data Privacy Rights to All Clients and Members Across the Globe PROVIDENCE, R.I., May 25, 2018 (GLOBE NEWSWIRE) -- Virgin Pulse, the leading global provider of digital employee health, wellbeing and engagement solutions, today announced that it has achieved compliance with the EU General Data Protection Regulation (GDPR) for the Virgin Pulse platform. The company has also appointed Associate Counsel Beatrice Botti as Data Protection Officer (DPO) to oversee the Virgin Pulse privacy program. With this achievement, Virgin Pulse leads the market as the first company in the wellbeing and engagement industry to fully meet the comprehensive standards of the new GDPR data privacy law. The company has completed a thorough review of its internal data collection, storage and handling processes and implemented enhancements to achieve GDPR compliance and give all Virgin Pulse customers and members greater control over their personal data. The GDPR is the firs

Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress25.5.2018 07:45Pressemelding

CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program. The speakers and agenda are as follows: Introduction Vincent M. Brandenburg, MD - University Hospital of the RWTH

Atico Reports Consolidated Financial Results for the First Quarter of 201824.5.2018 22:30Pressemelding

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX.V:ATY) (OTC:ATCMF) today announced its financial results for the three months ended March 31, 2018, posting a net income of $0.4 million. Fernando E. Ganoza, CEO and Director, commented, "The strong production and all-in sustaining cash cost of $1.85 achieved this quarter is not reflected in the financial results as a large concentrate shipment was delayed to the second quarter, along with the revenue associated with those tonnes. The shipping schedule is expected to stabilize during the second quarter, where we will then benefit from the additional shipped concentrate and recognized revenue. We anticipate strong financial results in the next quarter." Mr. Ganoza continued, "Our emphasis will continue to be on further strengthening our balance sheet, improving production costs and most importantly regional

Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16Pressemelding

London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h

SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00Pressemelding

MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom